| 包装 | 价格(元) |
| 500 µg | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
Cell lines | Raw264.7 macrophages |
Preparation Method | The cells were incubated with oxLDL (50 μg/mL), liraglutide (0.1, 0.5, 1 and 2 nmol/L) or exendin-3 (9-39) (1, 10 and 100 nM) alone, or in combination. |
Reaction Conditions | 1, 10 and 100 nM, 37℃, 48h |
Applications | Compared with the liraglutide group, oxLDL-stimulated Raw264.7 cells-treated with excendin-3 (1-100 nmol/L) showed an increased ROS and MDA, but a decreased SOD in a dose-dependent manner. |
Animal models | Male Wistar rats |
Preparation Method | Group I: sham surgery rats. Rats were not subjected to nerve transection and the left sciatic nerve was gently exposed and muscle and skin are sutured. Group II: PSNT-vehicle group (nerve-transected group infused with saline). Group III: PSNT-TEN group (nerve-transected group infused with teneligliptin). Group IV: PSNT-TEN + EXE group (nerve-transected group infused with teneligliptin + Exendin-3 (9–39) amide). Group IV: PSNT-Mor (nerve-transected group infused with Morphine). The animal behavior test was performed on Day -1 (Pre-surgery), Day 7 (7 days post-surgery), and Day 8, day 10, Day 12, and Day 14. |
Dosage form | 0.1 μg/1 μL/h, i.p. |
Applications | Co-infusion of 0.1 μg GLP-1 antagonist EXE did not reverse TEN-induced acute antinociception in PSNT rats. |
| 产品描述 | Exendin3(9-39) amide is a specific exendin receptor antagonist. Exendin-3 increased cellular cAMP levels and amylase release from dispersed acini from guinea pig pancreas.[1] In vitro experiment it shown that at 0.1-3 nM low concentrations caused a 12-fold increase in CAMP, whereas 0.3-3p~ higher concentrations caused an additional 24-fold increase in CAMP. Exendin-3 can interact with at least two receptors on guinea pig pancreatic acini; at >l00 nM high concentrations the peptide interacts with VIP receptors, so that a large increase in cAMP and stimulating amylase release; at 0.1-3 nM lower concentrations, the peptide interacts with a putative exendin receptor, result in causing a smaller increase in cAMP of undetermined function. And exendin-3(9-39) amide inhibits the actions of exendin-3 with IC 50 of 20 nM.[1]In oxLDL-stimulated Raw264.7 cells, treatment with 1-100 nmol/L excendin-3, it shown that an increased ROS and MDA, but a decreased SOD in a dose-dependent manner.[5]With 1 μM Exendin-3(9–39) pretreatment of the brain slice caused no change in the basal mPSC frequency, as well as no alteration in the basal firing rate was observed.[2] In vivo experiment it demonstrated that Exendin-3 (9-39) amide (10x7 mol l-1) inhibits GLP-1R but no effect on GLP-2 induced inotropism, lusitropism and coronary motility.[3] In vivo experiment it shown that treatment with 100 nM exendin-3 (9-39) by luminally, the acceleratory effect of GLP-1 was blocked.[4] References: |
m.cnreagent.com